{"id":661632,"date":"2026-10-22T02:44:30","date_gmt":"2026-10-22T02:44:30","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/661632\/"},"modified":"2026-10-22T02:44:30","modified_gmt":"2026-10-22T02:44:30","slug":"hse-could-be-saving-nearly-e150m-annually-by-using-more-biosimilar-drugs-the-irish-times","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/661632\/","title":{"rendered":"HSE could be saving nearly \u20ac150m annually by using more biosimilar drugs \u2013 The Irish Times"},"content":{"rendered":"<p class=\"c-paragraph paywall \"><a href=\"https:\/\/www.irishtimes.com\/tags\/hse\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/hse\/\">The Health Service Executive <\/a>could save \u20ac149 million annually by making greater use of lower-cost biosimilars \u2013 cheaper copies of expensive biological drugs \u2013 the Irish and UK head of Swiss pharma group <a href=\"https:\/\/www.irishtimes.com\/tags\/sandoz\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/sandoz\/\">Sandoz <\/a>has claimed.<\/p>\n<p class=\"c-paragraph paywall \">Diane DiGangi Trench, country head and general manager for Sandoz UK and Ireland, said biosimilar competition delivered an estimated \u20ac239 million in savings for the Irish healthcare system in 2025.<\/p>\n<p class=\"c-paragraph paywall \">A further \u20ac148.8 million in \u201cpotential annual savings\u201d could be realised through the greater uptake of biosimilars already available in Ireland and through the introduction of additional biosimilars already available in Europe, she said.<\/p>\n<p class=\"c-paragraph paywall \">Previously a unit of <a href=\"https:\/\/www.irishtimes.com\/tags\/sandoz\/\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.irishtimes.com\/tags\/sandoz\/\">Novartis<\/a>, Sandoz is the world\u2019s largest manufacturer of biosimilars. It acquired Cork pharma firm Rowex in 2024 and was the second-largest supplier of medicines to the HSE last year.<\/p>\n<p class=\"c-paragraph paywall \">Unlike generics, medicines made from living cells cannot be exactly copied and are referred to \u200bas biosimilars.<\/p>\n<p class=\"c-paragraph paywall \">\u201cIreland could capture a lot more savings &#8230; through greater uptake of the current biosimilars on the market as well as additional biosimilars being introduced,\u201d DiGangi Trench said.<\/p>\n<p class=\"c-paragraph paywall \">She noted that only 11 of 26 biosimilars (available in Europe) are marketed in Ireland, which represented the second-lowest uptake in Europe. Sandoz produces seven out of the 11 used here.<\/p>\n<p class=\"c-paragraph paywall \">DiGangi Trench said one of the reasons for the slow uptake in Ireland was the HSE\u2019s best-value biologics (BVB) medicines programme, which identifies lower-cost options within a specific drug class.<\/p>\n<p class=\"c-paragraph paywall \">The BVB tender process is, however, only triggered when there are at least four competitor drugs, including the originator, and it takes 240 days, considerably longer than in other countries.<\/p>\n<p class=\"c-paragraph paywall \">She noted that the ustekinumab drug, which is used in the treatment of psoriasis, had the potential to save the HSE almost \u20ac30 million annually, but the uptake here is just 30 per cent against a HSE target of 80 per cent.<\/p>\n<p class=\"c-paragraph paywall \">The same is true of several other biosimilars, she said.<\/p>\n<p class=\"c-paragraph paywall \">\u201cA lack of control within the system\u201d meant the potential savings \u201care just not happening\u201d, she said. In practice that means while some parts of the HSE are utilising the newer lower-cost drugs, others are not.<\/p>\n<p class=\"c-paragraph paywall \">\u201cIreland is spending more money than ever on healthcare and in trying to manage that growing pressure &#8230; it could capitalise on more opportunities around biosimilars to reduce its medicines expenditure,\u201d DiGangi Trench said.<\/p>\n<p><img decoding=\"async\" alt=\"\" class=\"c-image audio_image\" src=\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2026\/10\/1792637070_884_1784803479672-9ae96ac7-c636-4bcb-998c-c0aedcc60931.jpeg\"\/>Microsoft president Brad Smith: Ireland is \u201cwell-positioned for future of AI\u201d<\/p>\n<p class=\"c-paragraph paywall \">She predicted the next decade would be a \u201cgolden decade\u201d for biosimilars as the patents on many branded medicines expire.<\/p>\n<p class=\"c-paragraph paywall \">The company forecasts that approximately $650 billion (\u20ac597 billion) worth of branded medicines globally \u200bare due to lose patent exclusivity between now and 2036. DiGangi Trench compared it to the 2011-2016 patent cliff while noting that Sandoz wants to derive biosimilars from 100 products by 2040.<\/p>\n<p class=\"c-paragraph paywall \">\u201cThere is this huge wave of biosimilars coming on the market, and that\u2019s why it is in Ireland\u2019s best interest &#8230; to figure out how do you get uptake quicker, and how do you get more products to enter more quickly,\u201d she said.<\/p>\n<p class=\"c-paragraph paywall \">In North America, Sandoz\u2019s biosimilar sales grew 47 per cent in the first half of 2026, driven by sales of its new bone disease drug Wyost and osteoporosis drug Jubbonti.<\/p>\n<p class=\"c-paragraph paywall \">One of the largest opportunities for biosimilars and generics is the diabetes and obesity drug market.<\/p>\n<p class=\"c-paragraph paywall \">The US Food and Drug Administration recently agreed to review two Sandoz-made tirzepatide drugs \u200bthat, if approved, would rival obesity drugs made by Eli Lilly.<\/p>\n","protected":false},"excerpt":{"rendered":"The Health Service Executive could save \u20ac149 million annually by making greater use of lower-cost biosimilars \u2013 cheaper&hellip;\n","protected":false},"author":2,"featured_media":661633,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[25879,103,397,396,2120,61,60,8877],"class_list":["post-661632","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-food-and-drugs-administration","tag-health","tag-health-care","tag-healthcare","tag-hse","tag-ie","tag-ireland","tag-pharma"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/661632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=661632"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/661632\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/661633"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=661632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=661632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=661632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}